A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.

about

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer Germline breast cancer susceptibility gene mutations and breast cancer outcomes.Advances in the use of PARP inhibitor therapy for breast cancer

P2860

Q41309782-F0A2DC1C-25BD-495C-BA2A-E5D4BA04B2C0 Q54945937-0D6952F6-CA20-4C6B-B038-377F2817C12B Q57108063-06B90B4D-C3E9-4B37-8FE3-EF1470F4A4B3

P2860

A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.

Item

http://www.wikidata.org/entity/Q38850688

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A Phase II study of olaparib i ...... 'window of opportunity' trial.

@en

type

Item

label

A Phase II study of olaparib i ...... 'window of opportunity' trial.

@en

prefLabel

A Phase II study of olaparib i ...... 'window of opportunity' trial.

@en

P1476

A Phase II study of olaparib i ...... 'window of opportunity' trial.

@en

P2093

Alberto Bottini

http://www.w3.org/2001/XMLSchema#string

Alessandra Cocconi

http://www.w3.org/2001/XMLSchema#string

Andrea Ravelli

http://www.w3.org/2001/XMLSchema#string

Angela Gobbi

http://www.w3.org/2001/XMLSchema#string

Carla Strina

http://www.w3.org/2001/XMLSchema#string

Chiara Senti

http://www.w3.org/2001/XMLSchema#string

Daniele Generali

http://www.w3.org/2001/XMLSchema#string

Francesca Gussago

http://www.w3.org/2001/XMLSchema#string

Giovanni Allevi

http://www.w3.org/2001/XMLSchema#string

Laura Zanotti

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy.

Triple negative breast cancers have a reduced expression of DNA repair genes

Basal-like subtype and BRCA1 dysfunction in breast cancers.

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.

Advances in PARP inhibitors for the treatment of breast cancer.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

P304

2189-2193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0116

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giandomenico Roviello

P577

2016-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27324108

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.

about

P2860

P2860

A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921